[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-343222-105":59,"doc-detail-343222-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","high-sensitivity-ctdna-assays-in-genitourinary-malignancies-current-evidence-and-future-directions","High sensitivity ctDNA assays in genitourinary malignancies - current evidence and future directions","","Circulating tumor DNA (ctDNA) analysis has advanced cancer care by enabling rapid identification of actionable molecular targets, supported by a commercially emerging generation of tests with limits of detection around 0.01% variant allele frequency (vAF) or better. Such assays can detect radiologically occult molecular residual disease (MRD) after treatment and may guide neoadjuvant and adjuvant decisions. Evidence summarized across urothelial, renal, and testicular cancers indicates tumor-type dependent sensitivity and preserved tumor-informed MRD specificity, alongside ongoing prospective validation in biomarker-integral trials.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/high-sensitivity-ctdna-assays-in-genitourinary-malignancies-current-evidence-and-future-directions/343222/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/high-sensitivity-ctdna-assays-in-genitourinary-malignancies-current-evidence-and-future-directions/343222.png","ImageObject",300,407,{"name":92,"@type":93},"Levi","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-03","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What limits of detection define the high-sensitivity ctDNA tests discussed in the article?","Question",{"text":113,"@type":114},"The article describes a new generation of circulating DNA tests with a superior limit of detection of about 0.01% vAF or better.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How is molecular residual disease (MRD) expected to change treatment planning?",{"text":118,"@type":114},"MRD tests have the potential to revolutionize neoadjuvant and adjuvant treatment and can be used as tumor markers to assess disease response.",{"name":120,"@type":111,"acceptedAnswer":121},"Do the tests show consistent specificity across genitourinary tumor types?",{"text":122,"@type":114},"Tumor-informed MRD specificity is reported to be preserved across tumor types, approximately 98%–100%.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},343222,1790809105,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":34,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},7971461740909,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","High sensitivity ctDNA assays in genitourinary malignancies: current evidence and future directions  \nKartik R. Patel1, Soroush Rais-Bahrami1,2,3, Arnab Basu*,3,4,  \n1Department of Urology, University of Alabama at Birmingham, Heersink School of Medicine, Birmingham, AL 35233, United States, 2Department of Radiology, University of Alabama at Birmingham, Heersink School of Medicine, Birmingham, AL 35233, United States, 3O’Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Heersink School of Medicine, Birmingham, AL 35233, United States,  \n4Division of Hematology-Oncology, Department of Medicine, University of Alabama at Birmingham, Heersink School of Medicine, Birmingham, AL 35233, United States  \n* Corresponding author: Arnab Basu, MD, MPH, FACP, University of Alabama at Birmingham, Heersink School of Medicine, 1802 6th Avenue South, Birmingham, AL 35294-3412, USA ([abasu@uabmc.edu](abasu@uabmc.edu)) .  \nAbstract  \nIn the recent decade, analysis of circulating tumor DNA (ctDNA) has improved cancer care by allowing for rapid detection of actionable molecular targets. A new generation of circulating DNA tests is now becoming available commercially. These tests are characterized by a superior limit of detection of 0.01% vaF or better, allowing for the detection of radiologically occult molecular residual disease (MRD) . MRD tests have the potential to revolutionize neoadjuvant and adjuvant treatment. In addition, these tests can be used as tumor markers to assess disease response. We reviewed the current evidence for the use of high-sensitivity MRD assays with particular focus on the genitourinary tumors. Multiple studies have now been reported in urothelial, renal, and recently testicular carcinoma. We find that the sensitivity varies across tumor types in the adjuvant setting and may reach a high of 100% in urothelial cancer. Specificity in tumor-informed MRD appears to be preserved across tumor types (98%-100%) . Several trials are now prospectively validating MRD testing in biomarker integral studies, mainly in urothelial carcinoma.  \nKey words: circulating tumor DNA; molecular residual disease; minimal residual disease; urothelial carcinoma; renal cell carcinoma; prostate cancer.  \nImplications for practice  \nctDNA tests with high sensitivity and specificity are now entering clinical practice. These tests can be used to detect radiologically occult disease or minimal residual disease (MRD) after surgery. Several studies appear to support the use of MRD for identifying highrisk patients in urothelial carcinoma. Emerging data suggests that these assays may provide important prognostic information in other genitourinary malignancies as well.  \nThe first generation of ctDNA assays  \nWhile the presence of plasma cell free DNA (cfDNA) was first noted in 1948, it took many decades to show that circulating tumor DNA (ctDNA) could be separately analyzed, and that it could be correlated with clinical course of disease.1 Despite this, the clinical actionability of ctDNA remained in question until the investigation of molecular drivers of cancer and the development of agents targeting these alterations. In 2003 and 2004, targeted therapies for epidermal growth factor receptor (EGFR) alterations in lung cancer, gefitinib and erlotinib were developed and ctDNA offered an easy and potentially quicker route to determine if patients were candidates for these directed therapies. This paved the way for ctDNA sampling for specific molecular alterations, with these tests aptly called the “liquid biopsy.”2 The Roche Cobas Test for non-small cell lung cancer became the first US Food & Drug Administration approved plasma  \nctDNA liquid biopsy to evaluate EGFR alterations in 2016. In subsequent decades, treatments have been developed toward other targets such as BRCA1/BRCA2, ATM and KRAS, and genomic alterations such as TP53, RB, or PTEN, have been shown to have important prognostic implications for cancers. Expansion of these ac","cbCain6IAcdT27KL","https://ap.wps.com/l/cbCain6IAcdT27KL","pdf",271539,"English","# Abstract\n# Implications for practice\n# The first generation of ctDNA assays\n# High-sensitivity ctDNA assays","[{\"question\":\"What limits of detection define the high-sensitivity ctDNA tests discussed in the article?\",\"answer\":\"The article describes a new generation of circulating DNA tests with a superior limit of detection of about 0.01% vAF or better.\"},{\"question\":\"How is molecular residual disease (MRD) expected to change treatment planning?\",\"answer\":\"MRD tests have the potential to revolutionize neoadjuvant and adjuvant treatment and can be used as tumor markers to assess disease response.\"},{\"question\":\"Do the tests show consistent specificity across genitourinary tumor types?\",\"answer\":\"Tumor-informed MRD specificity is reported to be preserved across tumor types, approximately 98%–100%.\"}]","High sensitivity ctDNA assays in genitourinary malignancies - current evidence and future directions | PDF",1790050338,18,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9e3c6cb27c3476a89374243f6ec6a496.webp",983,1291,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4c5d3a5be1696d96f50fee7e5030d425.webp",982,1290,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/14d187adb4df8c2d9298d7641e32e3b0.webp",981,1289,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/836ea49da32dce9315936a20ca765cb3.webp",980,1287]